Pentraxin 3 and Non-Alcoholic Fatty Liver Disease in Egyptian Patients: Merits and Flaws

Albitar, Amr R; MahaRakha,; Emad, Nahla; Yamany, Ahmed

doi:10.5958/0976-5506.2019.04106.8

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For these reasons, NASH is a disease requiring early and accurate detection, routine follow-up and comprehensive medical intervention that must be distinguished from simple steatosis [4]. Liver biopsy is the gold standard test for NASH detection [5,6] but the use of liver biopsy routinely in clinical practices is difficult for many reasons including invasiveness, misdiagnosis, sampling error, cost and inter-observer variability [7]. So measurement and validation of non-invasive biomarkers that accurately diagnose, predict and monitor clinical outcomes are critically needed [7,8].…”

Section: Introductionmentioning

confidence: 99%

Serum Mir-34A and Mir-122 as an early non-invasive diagnostic marker for simple steatosis and NASH in comparison to FIB-4

NM¹,

TM²,

MMA³

et al. 2022

J Clin Images Med Case Rep

View full text Add to dashboard Cite

Early detection of simple steatosis and differentiating it from NASH is an important turning point for evaluation and management. Liver biopsy is the gold standard method, but it is unpractical for many reasons and not accepted by most patients. So, many noninvasive methods have been used including microRNAs and fibrosis score (Fib-4). Our study aimed to validate the usefulness of these biomarkers for the early diagnosis of simple steatosis, differentiating it from NASH and evaluating their performance in comparison to FIB-4.Sixty two patients who met the inclusion criteria and thirty healthy controls were evaluated by Routine laboratory tests, miRNA (122,34a), Fib-4 and Liver Stiffness Measurement (LSM). The diagnostic value of miRNAs and its correlations to clinical and laboratory data in NASH and simple steatosis were analyzed and compared with FIB-4. A simple model was developed, combining microRNA levels and hs-CRP. miR-122 and -34a levels showed differential values between simple steatosis and NASH patients (p<0.01) and correlated with hepatic histology. Combined microRNA expression profiles with hs-CRP had a higher potential of simple steatosis and NASH compared to other risk biomarkers (AUC > 0,990). We concluded that circulating miR-122 and -34a may act as a disease-specific noninvasive biomarker for NASH diagnosis. miRNA along with hs-CRP assigning a prediction panel with improved diagnostic value superior to FIB-4 in early recognition of NASH to tailor efficient therapeutic interventions.

show abstract